The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech ...

We recently compiled a list of the 10 Best Performing Biotech Stocks in 2024. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against ...

Due in major part to stock-based compensation, legal and patent services, and third-party consulting, G&A expenses increased from $8.9 million to $13.8 million. Viking Therapeutics, Inc. (NASDAQ ...

Also Read: Rare Disease-Focused Applied Therapeutics' Lead Candidate Govorestat Has Blockbuster Potential, Analyst Sees 140% Stock Upside The class action covers investors who purchased Applied ...

These ratings reflect expectations for the relative performance of Celldex Therapeutics compared to the broader market. Price Targets: Analysts set price targets as an estimate of a stock's future ...

William Blair maintains Viking Therapeutics as a top 2025 pick ... or new licensing deals could significantly affect its stock. William Blair remains confident that Viking offers a valuable ...

Cara Therapeutics is entering an all-stock deal to combine with private, clinical-stage biopharmaceutical company Tvardi Therapeutics. Tvardi will merge with a subsidiary of Cara under the terms ...

During the pre-market hours, Cara's stock is climbing 11.35 percent, to $0.27 on the Nasdaq. Cara Therapeutics NewsMORE Related Stocks ...

I believe, with a good risk tolerance, the risk-reward ratio of Keros Therapeutics is interesting because the price of the stock could ramp up if either: KER-050 confirms a longer duration of ...

Also Read: Viking Therapeutics Garners Analyst Support For ... data from competitors or new licensing deals could significantly affect its stock. William Blair remains confident that Viking ...

iTeos Therapeutics, Inc.'s lead candidate ... Given the promising data and financial runway, I maintain a Buy sentiment on ITOS stock, despite the inherent risks and market pessimism.